A detailed history of Ubs Group Ag transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Ubs Group Ag holds 2,900 shares of PRQR stock, worth $7,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,900
Previous 27,546 89.47%
Holding current value
$7,627
Previous $45,000 88.89%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.64 - $2.24 $40,419 - $55,207
-24,646 Reduced 89.47%
2,900 $5,000
Q2 2024

Aug 13, 2024

BUY
$1.65 - $2.39 $37,250 - $53,956
22,576 Added 454.25%
27,546 $45,000
Q1 2024

May 13, 2024

BUY
$1.89 - $2.85 $2,022 - $3,049
1,070 Added 27.44%
4,970 $11,000
Q4 2023

Feb 09, 2024

SELL
$1.15 - $2.21 $7,065 - $13,578
-6,144 Reduced 61.17%
3,900 $7,000
Q3 2023

Nov 09, 2023

BUY
$1.3 - $1.77 $6,971 - $9,492
5,363 Added 114.57%
10,044 $13,000
Q2 2023

Aug 11, 2023

BUY
$1.62 - $2.32 $1,751 - $2,507
1,081 Added 30.03%
4,681 $7,000
Q1 2023

May 12, 2023

BUY
$1.99 - $3.66 $1,305 - $2,400
656 Added 22.28%
3,600 $7,000
Q4 2022

Feb 08, 2023

SELL
$0.8 - $3.7 $1,723 - $7,969
-2,154 Reduced 42.25%
2,944 $10,000
Q3 2022

Nov 10, 2022

BUY
$0.74 - $0.89 $3,772 - $4,537
5,098 New
5,098 $4,000
Q1 2022

May 16, 2022

SELL
$0.9 - $8.39 $75,894 - $707,503
-84,327 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$6.58 - $8.44 $64,411 - $82,619
-9,789 Reduced 10.4%
84,327 $675,000
Q3 2021

Nov 15, 2021

BUY
$5.16 - $8.47 $165,651 - $271,912
32,103 Added 51.77%
94,116 $787,000
Q2 2021

Aug 13, 2021

SELL
$5.75 - $7.59 $164,461 - $217,089
-28,602 Reduced 31.56%
62,013 $418,000
Q1 2021

May 12, 2021

SELL
$4.14 - $9.22 $1.58 Million - $3.52 Million
-381,488 Reduced 80.81%
90,615 $599,000
Q4 2020

Feb 11, 2021

SELL
$3.58 - $4.85 $22,274 - $30,176
-6,222 Reduced 1.3%
472,103 $1.98 Million
Q3 2020

Nov 12, 2020

SELL
$4.79 - $6.3 $18,877 - $24,828
-3,941 Reduced 0.82%
478,325 $2.29 Million
Q2 2020

Jul 31, 2020

SELL
$4.5 - $6.53 $1,543 - $2,239
-343 Reduced 0.07%
482,266 $2.93 Million
Q1 2020

May 01, 2020

SELL
$5.25 - $9.9 $132,704 - $250,242
-25,277 Reduced 4.98%
482,609 $2.65 Million
Q4 2019

Feb 14, 2020

BUY
$5.84 - $10.51 $328,167 - $590,588
56,193 Added 12.44%
507,886 $5.03 Million
Q3 2019

Nov 14, 2019

SELL
$5.76 - $9.44 $86,929 - $142,468
-15,092 Reduced 3.23%
451,693 $2.6 Million
Q2 2019

Aug 14, 2019

BUY
$9.1 - $15.55 $4.25 Million - $7.26 Million
466,785 New
466,785 $4.25 Million
Q1 2019

May 14, 2019

SELL
$12.5 - $18.48 $35.7 Million - $52.7 Million
-2,854,433 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$15.25 - $22.4 $43.5 Million - $63.9 Million
2,854,207 Added 1262923.5%
2,854,433 $45 Million
Q3 2018

Nov 14, 2018

BUY
$6.45 - $21.6 $1,457 - $4,881
226 New
226 $4,000
Q2 2018

Aug 14, 2018

SELL
$2.95 - $7.45 $8,546 - $21,582
-2,897 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$2.9 - $3.5 $2,908 - $3,510
1,003 Added 52.96%
2,897 $9,000
Q4 2017

Feb 14, 2018

SELL
$2.8 - $4.8 $1,450 - $2,486
-518 Reduced 21.48%
1,894 $6,000
Q3 2017

Nov 14, 2017

BUY
$4.35 - $6.45 $2,810 - $4,166
646 Added 36.58%
2,412 $12,000
Q2 2017

Aug 14, 2017

BUY
N/A
1,766
1,766 $9,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $188M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.